Mithra Announces FDA Filing Acceptance of New Drug Application for Estelle® in the US

/in , /by

Liege, Belgium, 24 June 2020 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the New Drug Application (NDA) for Estelle® has been accepted for review by the US Food and Drug Administration (FDA). The FDA is expected to complete its review in the first half of calendar […]

Read more →

Information on the Total Number of Voting Rights (Denominator)

/in , /by

Liege, Belgium, 23 June 2020 – 17:45 CEST –In accordance with article 15 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Mithra Pharmaceuticals SA (the “Company” or “Mithra”) announces the following information, following the […]

Read more →

Notice of Extraordinary Shareholders’ Meeting on 22th July 2020 Regarding Proposed Warrant Plans

/in , /by

Liege, Belgium, 19 June 2020 – 17:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the publication of the invitation to its Extraordinary General Shareholders’ Meeting (EGM) that will be held on Wednesday July 22 2020 at 2:00 PM (CET) in Flémalle 57 rue de l’Expansion (Belgium). The agenda […]

Read more →

Mithra Successfully Raises EUR 65 Million By Means of a Private Placement via an Accelerated Bookbuild Offering

/in /by

Liège, Belgium, 18 June 2020 20:30 CEST – Mithra Pharmaceuticals SA (the “Company” or “Mithra”), a company specialized in Women’s Health (Euronext Brussels: MITRA), announces today that it successfully raised an amount of EUR 65.0 million in gross proceeds by means of a private placement via an accelerated bookbuild offering of 3,421,052 new shares (being […]

Read more →

Mithra Launches Capital Increase By Means of a Private Placement via an Accelerated Bookbuild Offering and Provides an Update on its Financing Strategy

/in , /by

Launch of a capital increase of approximately EUR 55 million by means of a private placement via an accelerated bookbuild offering Loan of EUR 20 million secured, in addition to the recent capital commitment agreement with LDA for up to EUR 50 million Last building blocks in the Company’s financing strategy in becoming a commercial […]

Read more →

Mithra Signs LSA for Commercialization of Tibelia® in Liechtenstein and Switzerland

/in , /by

Mithra grants license to Spirig Healthcare (Stada Group) for commercialization of its hormone treatment Tibelia® in Liechtenstein and Switzerland Tibelia® is currently marketed in about 30 countries through existing license and supply agreements Liege, Belgium, 11 June 2020 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces it […]

Read more →

Mithra Issues First Put Option Notice Under Capital Agreement with LDA Capital

/in , /by

Liege, Belgium, 05 June 2020 – 7:30 CEST – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that following the signature of the capital commitment agreement with LDA Capital Limited announced on April 24, 2020, the Board of Directors approved on May 22, 2020 an increase to the Company’s […]

Read more →

Mithra Signs License and Supply Agreement with Mayne Pharma for Commercialization of Estelle in Australia

/in , /by

Consolidation of partnership with Mayne Pharma for commercialization of the combined oral contraceptive E4/DRSP (Estelle®) in Australia Mithra eligible for milestone and license fees of up to EUR 3.5 million Preparation ongoing for the commercial launch of Mithra’s oral contraceptive in the U.S. and Australia, targeted for H1 and H2 2021 respectively Liege, Belgium, 28 […]

Read more →

Mithra Launches a Research Programme on Estetrol’s Effect in Covid-19 Treatment

/in , /by

Women are more likely than men to be spared by Covid-19, with less severe infections and lower mortality rates Protective role of estrogen against human coronaviruses already demonstrated during the SARS infection, and currently being tested in the U.S. among hospitalized patients Mithra plans to develop a research program to study Estetrol (E4) mechanism of […]

Read more →

Mithra and Searchlight Pharma Announce Filing of New Drug Submission for Estelle® in Canada

/in , /by

Searchlight Pharma’s New Drug Submission for a novel combined oral contraceptive (COC) accepted for review by Health Canada Innovative product candidate developed by Mithra containing the unique native estrogen Estetrol (E4) and drospirenone (DRSP) Potential commercialization in Canada under the trademark Nextstellis® expected in mid 2021 LIEGE (Belgium) and MONTREAL (Canada), 20 May 2020 – […]

Read more →